Cargando…
Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?
Autores principales: | Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Harari, Gil, Gurevich, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549192/ https://www.ncbi.nlm.nih.gov/pubmed/34742628 http://dx.doi.org/10.1016/j.ejim.2021.10.027 |
Ejemplares similares
-
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021) -
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021) -
Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
por: Achiron, Anat, et al.
Publicado: (2021) -
In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab
por: Achiron, Anat, et al.
Publicado: (2023) -
SARS-CoV-2 antibody dynamics and B-cell memory response over time in COVID-19 convalescent subjects
por: Achiron, Anat, et al.
Publicado: (2021)